<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Chromatogr B Analyt Technol Biomed Life Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Chromatogr. B Analyt. Technol. Biomed. Life Sci</journal-id><journal-title-group><journal-title>Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences</journal-title></journal-title-group><issn pub-type="ppub">1570-0232</issn><issn pub-type="epub">1873-376X</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27362994</article-id><article-id pub-id-type="pmc">4955110</article-id><article-id pub-id-type="publisher-id">S1570-0232(16)30393-2</article-id><article-id pub-id-type="doi">10.1016/j.jchromb.2016.06.017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Liquid chromatography&#x02013;mass spectrometry for measuring deoxythioguanosine in DNA from thiopurine-treated patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Coulthard</surname><given-names>Sally A.</given-names></name><email>sally.coulthard@newcastle.ac.uk</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Berry</surname><given-names>Phil</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>McGarrity</surname><given-names>Sarah</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Ansari</surname><given-names>Azhar</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Redfern</surname><given-names>Christopher P.F.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK</aff><aff id="aff0010"><label>b</label>Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK</aff><aff id="aff0015"><label>c</label>Gastroenterology Dept., East Surrey Hospital, Redhill, East Surrey, UK</aff><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author. Institute of Cellular Medicine, Newcastle University, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUK <email>sally.coulthard@newcastle.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>15</day><month>8</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><day>15</day><month>8</month><year>2016</year></pub-date><volume>1028</volume><fpage>175</fpage><lpage>180</lpage><history><date date-type="received"><day>29</day><month>2</month><year>2016</year></date><date date-type="rev-recd"><day>26</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple"><list-item id="lsti0005"><label>&#x02022;</label><p>Thiopurines are effective immunosuppressant drugs.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p>Monitoring of thiopurines is needed for research and clinical use.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p>A sensitive assay of DNA-incorporated deoxythioguanosine is described.</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p>This method assays thiopurine nucleotides in DNA from nucleated blood cells.</p></list-item></list></p></abstract><abstract id="abs0010"><p>Adverse reactions and non-response are common in patients treated with thiopurine drugs. Current monitoring of drug metabolite levels for guiding treatment are limited to analysis of thioguanine nucleotides (TGNs) in erythrocytes after chemical derivatisation. Erythrocytes are not the target tissue and TGN levels show poor correlations with clinical response. We have developed a sensitive assay to quantify deoxythioguanosine (dTG) without derivatisation in the DNA of nucleated blood cells. Using liquid chromatography and detection by tandem mass spectrometry, an intra- and inter-assay variability below 7.8% and 17.0% respectively were achieved. The assay had a detection limit of 0.0003125&#x000a0;ng (1.1 femtomoles) dTG and was quantified in DNA samples relative to endogenous deoxyadenosine (dA) in a small group of 20 patients with inflammatory bowel disease, all of whom had been established on azathioprine (AZA) therapy for more than 25 weeks. These patients had dTG levels of 20&#x02013;1360&#x000a0;mol dTG/10<sup>6</sup>&#x000a0;mol dA; three patients who had not started therapy had no detectable dTG. This method, comparable to previous methods in sensitivity, enables the direct detection of a cytotoxic thiopurine metabolite without derivatisation in an easily obtainable, stable sample and will facilitate a better understanding of the mechanisms of action of these inexpensive yet effective drugs.</p></abstract><kwd-group id="kwd0005"><title>Abbreviations</title><kwd>ALL, Acute childhood leukemia</kwd><kwd>6-MP or MP, 6-mercaptopurine</kwd><kwd>AZA, azathioprine</kwd><kwd>IBD, inflammatory bowel disease</kwd><kwd>MeMP, methylmercaptopurine</kwd><kwd>MeMP-d3, Methymercaptopurine-D3</kwd><kwd>TIMP, thioinosine monophosphate</kwd><kwd>TIDP, thioinosine diphosphate</kwd><kwd>TITP, thioinosine triphosphate</kwd><kwd>TXMP, thioxanthine monophosphate</kwd><kwd>TGMP, thioguanosine monophosphate</kwd><kwd>TGDP, thioguanosine diphosphate</kwd><kwd>TGTP, thioguanosine triphosphate</kwd><kwd>IMPDH, inosine-monophosphate dehydrogenase</kwd><kwd>TPMT, thiopurine methyl-transferase</kwd><kwd>HGPRT, hypoxanthine-guanine phosphoribosyl transferase</kwd><kwd>ITPase, inosine tri-phosphatase</kwd><kwd>GMPS, guanosine monophosphate synthetase</kwd><kwd>dTG, deoxythioguanosine</kwd><kwd>TGN, thioguanine nucleotide</kwd><kwd>NBCs, nucleated blood cells</kwd><kwd>CD, Crohn&#x02019;s disease</kwd><kwd>UC, ulcerative colitis</kwd><kwd>RBC, red blood cell</kwd><kwd>QC, Quality control</kwd></kwd-group><kwd-group id="kwd0010"><title>Keywords</title><kwd>Azathioprine</kwd><kwd>Mercaptopurine thiopurine</kwd><kwd>Drug monitoring</kwd><kwd>Tandem mass spectrometry</kwd><kwd>LC&#x02013;MS/MS</kwd><kwd>Thioguanine nucleotides</kwd><kwd>DNA</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p>Since their introduction into clinical practice more than six decades ago, the purine analogues mercaptopurine (MP; 3,7-dihydropurine-6-thione), azathioprine (AZA; 6-[3-methyl-5-nitroimidazol-4-yl]sulfanyl-7H-purine) and thioguanine (TG; 2-amino-3,7-dihydropurine-6-thione) have been used extensively in the treatment of diseases such as acute childhood leukaemia (ALL) <xref rid="bib0005" ref-type="bibr">[1]</xref>, inflammatory bowel disease (IBD) <xref rid="bib0010" ref-type="bibr">[2]</xref>, <xref rid="bib0015" ref-type="bibr">[3]</xref>, auto-immune hepatitis <xref rid="bib0020" ref-type="bibr">[4]</xref> and rheumatoid arthritis <xref rid="bib0025" ref-type="bibr">[5]</xref>. Thiopurines require activation by hypoxanthine-guanine phosphoribosyl transferase (HGPRT, E.C. 2.4.2.8) followed by multi-step metabolism to TGNs or methylated products to exert their clinical effect (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>). Two key enzymes mediating thiopurine metabolism are inosine-monophosphate dehydrogenase (IMPDH) which is only present in nucleated cells <xref rid="bib0030" ref-type="bibr">[6]</xref>, and thiopurine methyltransferase (TPMT) <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>, <xref rid="bib0045" ref-type="bibr">[9]</xref>. If treated with normal thiopurine doses, patients lacking TPMT activity develop high TGN levels that can lead to life-threatening leukopenia <xref rid="bib0050" ref-type="bibr">[10]</xref>, <xref rid="bib0055" ref-type="bibr">[11]</xref>, <xref rid="bib0060" ref-type="bibr">[12]</xref>. Cytotoxicity is mediated by a variety of mechanisms, including inhibition of <italic>de novo</italic> purine synthesis, disruption of G-protein signalling <xref rid="bib0065" ref-type="bibr">[13]</xref> and incorporation of thioguanine nucleotides (TGNs) into DNA with subsequent mismatching to thymidine, causing cell death by post-replicative mismatch repair <xref rid="bib0070" ref-type="bibr">[14]</xref>, <xref rid="bib0075" ref-type="bibr">[15]</xref>, <xref rid="bib0080" ref-type="bibr">[16]</xref>.</p><p>Given a low therapeutic index and the wide variation in clinical response, including potential for life-threatening toxicity in patients with very low or absent TPMT activity, it is important to monitor and optimise thiopurine drug levels. Assays have been developed to measure metabolites in a range of cellular compartments including erythrocytes <xref rid="bib0085" ref-type="bibr">[17]</xref>, <xref rid="bib0090" ref-type="bibr">[18]</xref>, <xref rid="bib0095" ref-type="bibr">[19]</xref>, <xref rid="bib0100" ref-type="bibr">[20]</xref>, whole blood <xref rid="bib0105" ref-type="bibr">[21]</xref> and leukocyte DNA <xref rid="bib0110" ref-type="bibr">[22]</xref>, <xref rid="bib0115" ref-type="bibr">[23]</xref> but ease of access to erythrocytes coupled with simple HPLC separation techniques has meant that quantifying thiopurine metabolites in erythrocytes has become the standard method for therapeutic monitoring. However, despite its value for assessing patient compliance, there is significant debate about concordance with therapeutic response in IBD <xref rid="bib0120" ref-type="bibr">[24]</xref>, <xref rid="bib0125" ref-type="bibr">[25]</xref>, <xref rid="bib0130" ref-type="bibr">[26]</xref>. Non-concordance can arise from methodological issues <xref rid="bib0135" ref-type="bibr">[27]</xref> and differences in metabolism between nucleated versus enucleated cells which lack the critical IMPDH enzyme. Therefore, the incorporation of deoxythioguanosine (dTG) into the DNA of nucleated cells may be a more relevant marker of therapeutic response. The aim of this study was to develop a sensitive assay for DNA-incorporated dTG in nucleated blood cells which could be developed for clinical use to study the mechanisms of response to thiopurines.</p></sec><sec id="sec0010"><label>2</label><title>Materials and methods</title><sec id="sec0015"><label>2.1</label><title>Chemicals and enzymes</title><p>The dTG standard was from Carbosynth (Compton, UK); deoxyadenosine (dA) was from Sigma-Aldrich (Gillingham, UK) and deuterated 6-methylmercaptopurine (MeMP-d3) from Toronto Research Chemicals (Ontario, Canada). HPLC grade acetic acid was from Fisher Scientific (Loughborough, UK). Calf intestinal alkaline phosphatase and nuclease P1 from <italic>Penicillium citrinum</italic> were from Sigma-Aldrich, as were all other reagents.</p></sec><sec id="sec0020"><label>2.2</label><title>Patient blood sample collection and processing</title><p>Clinical samples were from a small cohort of adult IBD patients (10 with Crohn&#x02019;s Disease [CD] and 10 Ulcerative Colitis [UC]) treated with a range of doses of AZA, all of whom had been in clinical remission for more than 6 months with no therapeutic complications; three untreated IBD patients were used as controls. The study protocol was approved by NRES Committee South West &#x02212; Cornwall &#x00026; Plymouth, Bristol Research Ethics Committee Centre. DNA was isolated from whole blood collected in EDTA tubes, or from negative-control MOLT4 (T-acute lymphoblastic leukaemia) cells, using previously published methods <xref rid="bib0140" ref-type="bibr">[28]</xref>. Briefly whole blood was mixed with 3 vols of ice-cold buffer A (10&#x000a0;mM Tris, 320&#x000a0;mM sucrose, 5&#x000a0;mM Mg Cl<sub>2</sub> 1% Triton&#x000a0;&#x000d7;&#x000a0;100&#x000a0;pH 8) and centrifuged at 1730<italic>g</italic> for 10&#x000a0;min at 4 &#x000b0;C. The supernatant was removed and the remaining pellet re-suspended in 1&#x000a0;mL buffer B (400&#x000a0;mM Tris, 60&#x000a0;mM EDTA, 150&#x000a0;mM NaCl and 1% SDS pH 8) plus 0.5&#x000a0;mL of 5&#x000a0;M sodium perchlorate, mixed for 10&#x000a0;min, then incubated at 65 &#x000b0;C for 45&#x000a0;min. To this, 2.5&#x000a0;mL of chloroform was added and mixed for 20&#x000a0;min prior to centrifugation at 432<italic>g</italic> for 10&#x000a0;min at 4 &#x000b0;C. The top layer was removed and 2.5 vols of ethanol added to precipitate the DNA which was spooled out, air-dried and re-suspended in 100&#x02013;200&#x000a0;&#x003bc;L of double-deionised water. The red blood cell (RBC) TGN assays were performed by a commercial laboratory at the City Hospital Birmingham (cityassays.org). Other tests were part of routine clinical care at the six hospitals contributing samples.</p><p>DNA was digested with P1 nuclease and alkaline phosphatase to release nucleosides for LC&#x02013;MS/MS analysis using previously-described methods <xref rid="bib0145" ref-type="bibr">[29]</xref>. Briefly, samples were prepared in the following manner: 5&#x000a0;&#x003bc;g DNA in a total volume of 100&#x000a0;&#x003bc;L double-deionised water, containing 124.38&#x000a0;ng/mL (0.735&#x000a0;&#x003bc;M) Methymercaptopurine-D3 (MeMP-d3) as an internal standard to control for extraction efficiency, was denatured by heating to 100 &#x000b0;C for 5&#x000a0;min. After chilling on ice for 2&#x000a0;min, 10&#x000a0;&#x003bc;L of 10X digestion buffer (500&#x000a0;mM sodium acetate, 10&#x000a0;mM MgCl<sub>2</sub> pH 5.3) and 5&#x000a0;&#x003bc;L of 0.12U/&#x003bc;L nuclease P1 was added and incubated for 1&#x000a0;h at 50 &#x000b0;C. Finally, 20&#x000a0;&#x003bc;L of 1&#x000a0;M Tris-HCl and 1&#x000a0;&#x003bc;L of alkaline phosphatase (1U/mL) were added to each sample and incubated for 30&#x000a0;min at 40 &#x000b0;C. MeMP-d3 was used as an internal standard as it was the only deuterated thiopurine metabolite available commercially at the time.</p></sec><sec id="sec0025"><label>2.3</label><title>LC&#x02013;MS/MS analysis of thioguanine incorporated into DNA</title><p>Chromatographic separation of dTG, dA and MeMP-d3 was achieved using a Prominence HPLC (Shimadzu, Kyoto, Japan) with an XSelect HSS T3 4.6&#x000a0;&#x000d7;&#x000a0;100&#x000a0;mm 3.5&#x000a0;&#x003bc;m and a VanGuard cartridge 3.9&#x000a0;&#x000d7;&#x000a0;5&#x000a0;mm 3.5&#x000a0;&#x003bc;m guard column (Waters, Massachusetts, USA) maintained at 30 &#x000b0;C. Analytes were eluted with HPLC grade (Sigma-Aldrich) mobile phases comprising 0.05% aqueous formic acid (A) and 0.05% formic acid in acetonitrile (B). The flow rate was 0.5&#x000a0;mL/min and the mobile phase system consisted of a starting condition of 1% buffer B increasing to 3% at 1.1&#x000a0;min, 8% at 2.4&#x000a0;min and increasing to a maximum of 30% at 4.1&#x000a0;min then decreasing to 5% at 4.5&#x000a0;min, maintained until 5.5&#x000a0;min then decreasing to 1% for an equilibration period of 2.5&#x000a0;min. An API4000 triple quadrupole LC&#x02013;MS/MS (Applied Biosystems, California, USA) was used for analysis with electrospray ionisation performed in positive ion mode using nitrogen gas with the following optimum settings: curtain gas, 20; ion source gas 1, 10; ion source gas 2, 10; ion spray voltage, 5500; collision gas, 6; entrance potential, 10; ionisation temperature, 300&#x02218;C. Mass transitions and optimised MS/MS parameters for analyte quantification are summarised in <xref rid="tbl0005" ref-type="table">Table 1</xref>.</p><p>Standards were prepared at 100,000&#x000a0;ng/mL dA and 2000&#x000a0;ng/mL dTG before serial dilution in double-deionised water to 390&#x000a0;ng/mL dA and 3.9&#x000a0;ng/mL dTG, respectively, after which dA standards were diluted 1/100 and dTG standards 1/10 in double-deionised water prior to injection. Quality controls (QCs) were diluted using 10&#x000a0;&#x000d7;&#x000a0;digestion buffer as for patient samples at three concentrations; these were then diluted either 1/10 (for dTG) or 1/100 (for dA) in double-deionised water to yield concentrations of high (40,000&#x000a0;ng/mL dA: 400&#x000a0;ng/mL dTG), medium (4000&#x000a0;ng/mL dA: 40&#x000a0;ng/mL dTG) and low (400&#x000a0;ng/mL dA: 4&#x000a0;ng/mL dTG) concentration standards prior to injection.</p><p>Standards and controls, as for patient samples, contained 124.38&#x000a0;ng/mL MeMP-d3 prior to 1/10 or 1/100 dilution. Samples were diluted in double-deionised water 1/10 (for dTG determination) and 1/100 (for dA) to avoid signal saturation on the mass spectrometer. Sample injections represented 0.2&#x000a0;&#x003bc;g patient DNA per injection for dTG determination and 0.02&#x000a0;&#x003bc;g DNA for dA. Standards were analysed in duplicate, QCs in triplicate, and negative control MOLT4 DNA and samples were analysed in singlicate, all with a 50&#x000a0;&#x003bc;L injection volume. Samples where the internal standard was outside an acceptable range (within 15% of the expected value) were discarded. For measurement of dTG, background at the retention time for dTG in extracts of negative control MOLT4 DNA (loaded as for patient DNA) was subtracted from the dTG peak in patient samples (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>).</p></sec><sec id="sec0030"><label>2.4</label><title>LC&#x02013;MS/MS validation</title><p>Method validation was adapted from the 2001 FDA guidelines <xref rid="bib0150" ref-type="bibr">[30]</xref>. Not all validation parameters could be determined because calibrators consisting of dTG incorporated into DNA are not obtainable and it is not possible to have a processed sample containing the DNA matrix without the presence of dA.</p><sec id="sec0035"><label>2.4.1</label><title>Selectivity</title><p>As dA is always present in processed DNA samples, the absence of dTG in negative-control MOLT4 cells and in patients not on thiopurine therapy indicates selectivity.</p></sec><sec id="sec0040"><label>2.4.2</label><title>Accuracy and precision</title><p>QC solutions of analytes were prepared in DNA digestion buffer at the concentrations 400, 40 and 4&#x000a0;ng/mL for dTG and 40,000, 4000 and 400&#x000a0;ng/mL for dA, equating to 2, 0.2 and 0.02&#x000a0;ng for dTG and 20, 2 and 0.2&#x000a0;ng for dA per injection, and used to determine intra- (5 separate analytical runs containing 5 QCs per concentration) and inter-assay (10 QCs per concentration) accuracy and precision from multiple injections (<xref rid="tbl0010" ref-type="table">Table 2</xref>).</p></sec><sec id="sec0045"><label>2.4.3</label><title>Recovery and sample dilution</title><p>It is not possible to obtain matrix free of dA, and the addition of exogenous calibrators would not be a suitable equivalent measure of the efficiency of extraction from DNA; therefore, we could not perform a full recovery analysis. The testing of different DNA extracts from the same sample and different amounts of DNA from the same sample gave a stable ratio between dA and dTG (<xref rid="tbl0015" ref-type="table">Table 3</xref>) and this indicates that extraction efficiency is maintained across both analytes.</p></sec><sec id="sec0050"><label>2.4.4</label><title>Freeze and thaw stability</title><p>QC solutions of analytes were prepared in DNA digestion buffer as described above at the concentrations 400, 40 and 4&#x000a0;ng/mL for dTG and 40,000, 4000 and 400&#x000a0;ng/mL for dA, stored at &#x02212;20&#x000a0;&#x000b0;C and subjected to between 1 and 3 freeze thaw cycles, each of 24&#x000a0;h duration. The QCs were then thawed and analysed on the same analytical run following the third freeze thaw cycle. All results were within 15% of expected values (<xref rid="tbl0020" ref-type="table">Table 4</xref>).</p></sec><sec id="sec0055"><label>2.4.5</label><title>Short-Term temperature stability</title><p>QC solutions of analytes were prepared in DNA digestion buffer at the concentrations 400, 40 and 4&#x000a0;ng/mL for dTG and 40,000, 4000 and 400&#x000a0;ng/mL for dA and tested after 24&#x000a0;h incubation at 4 &#x000b0;C (<xref rid="tbl0025" ref-type="table">Table 5</xref>).</p></sec></sec><sec id="sec0060"><label>2.5</label><title>Statistical analysis</title><p>Data were analysed using R <xref rid="bib0155" ref-type="bibr">[31]</xref>. Residuals from linear and non-linear models of dTG versus drug dose were not normally distributed (Shapiro-Wilks test, P&#x000a0;&#x0003c;&#x000a0;0.01) and, therefore, non-parametric Kendall&#x02019;s rank correlation <xref rid="bib0160" ref-type="bibr">[32]</xref> was used for all analyses.</p></sec></sec><sec id="sec0065"><label>3</label><title>Results</title><p>We report here a sensitive LC&#x02013;MS/MS method for measuring, without derivatisation, the thiopurine metabolite, dTG, in DNA isolated from whole blood of patients with CD or UC treated with AZA (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>). The method range was from 0.0975&#x000a0;ng to 50&#x000a0;ng injected for dA and from 0.000625&#x000a0;ng to 10&#x000a0;ng injected for dTG, with R<sup>2</sup>&#x000a0;&#x0003e;&#x000a0;0.99 for the standard curves (<xref rid="tbl0010" ref-type="table">Table 2</xref>). There was no matrix effect and no concentration effect on the ratio between dTG and dA (<xref rid="tbl0015" ref-type="table">Table 3</xref>). Three quality controls containing standards made in digestion buffer at low, medium and high concentrations within the standard curve range (duplicates at each concentration per run) were included in all runs; the intra-day variation was&#x02009;&#x0003c;7.8% and 11.9% for dA and dTG, respectively, and the inter-day variation was&#x02009;&#x0003c;17.0% and 15.9% for dA and dTG, respectively (<xref rid="tbl0010" ref-type="table">Table 2</xref>). The limit of detection (LOD) for dTG standards was 0.0003125&#x000a0;ng and lowest limit of quantification (LLOQ) 0.000625&#x000a0;ng (<xref rid="tbl0010" ref-type="table">Table 2</xref>). In the patient samples, dA was at very high concentrations and, therefore, in the standard mixtures dA was used at 100-fold higher levels than dTG to achieve appropriate standard curve ranges for both analytes, and samples were diluted 10-fold for dA determination relative to dTG determination. Incorporation of dTG into the DNA was reported as moles dTG per 10<sup>6</sup> moles dA, after subtraction of background at the dTG retention time using digested DNA from untreated MOLT4 cells, and was detectable in 0.2&#x000a0;&#x003bc;g patient DNA per LC&#x02013;MS/MS injection. Patients included were established on AZA therapy for more than 6 months and were in clinical remission according to the treating physician. For this cohort of patients, the incorporated dTG levels varied from 20 to 1360&#x000a0;mol dTG/10<sup>6</sup>&#x000a0;moles dA; expressed in the units used by Jacobson et al. <xref rid="bib0165" ref-type="bibr">[33]</xref>, this represents 14&#x02013;940&#x000a0;fmol/&#x003bc;g DNA (median 113; <xref rid="tbl0030" ref-type="table">Table 6</xref>). Within this small group of patients there was no significant positive correlation between dTG levels and drug dose (Kendall&#x02019;s rank correlation coefficient P&#x000a0;=&#x000a0;0.143), although further studies with a larger sample size are warranted. There were no indications for potential relationships between dTG levels and RBC TGN measurements (Kendall, P&#x000a0;=&#x000a0;0.85) or TPMT activity (Kendall, P&#x000a0;=&#x000a0;0.72). Patients who were not on AZA treatment had no detectable dTG in their DNA (<xref rid="tbl0030" ref-type="table">Table 6</xref>).</p></sec><sec id="sec0070"><label>4</label><title>Discussion</title><p>The method presented here has good sensitivity for dTG detection in DNA from whole blood with dTG levels expressed relative to an endogenous reference (dA) for sample loading; only 0.2&#x000a0;&#x003bc;g DNA was required per injection, with intra- and inter-assay calibration provided by commercially available standards. Using this approach, we were able to quantify DNA-incorporated dTG directly in the DNA of adult patients with IBD. Jacobsen et al. <xref rid="bib0165" ref-type="bibr">[33]</xref> have developed a similar assay but this requires derivatisation before analysis, necessitating standard dTG-incorporated DNA to control for variation in the derivatisation reaction. Nevertheless, both methods appear to have comparable sensitivity with respect to analyte detection.</p><p>For the samples from children with ALL treated with MP Jacobson et al. <xref rid="bib0165" ref-type="bibr">[33]</xref> reported incorporated dTG amounts of 45&#x02013;1190 fmol TG/&#x003bc;g DNA (median 377). Ebbesen et al. <xref rid="bib0170" ref-type="bibr">[34]</xref> reported similar values for standard- and intermediate risk childhood ALL patients on the NOPHO-ALL2008 protocol <xref rid="bib0175" ref-type="bibr">[35]</xref>. For the adult IBD patients reported here, DNA-incorporated dTG quantities, expressed in the same units, were 14&#x02013;940 fmol/&#x003bc;g DNA. The MP dose (NOPHO-ALL2008 protocol <xref rid="bib0175" ref-type="bibr">[35]</xref>) received by patients whose samples were used by Ebbesen et al. <xref rid="bib0170" ref-type="bibr">[34]</xref> was similar to guidelines for adult IBD patients <xref rid="bib0180" ref-type="bibr">[36]</xref>. Therefore, incorporated dTG amounts were, on the whole, comparable in these childhood ALL and adult IBD patients using different methods, despite differences in disease biology and patient age. Using their derivatisation assay <xref rid="bib0165" ref-type="bibr">[33]</xref>, Ebbesen et al. <xref rid="bib0170" ref-type="bibr">[34]</xref> reported that DNA-TGNS were independent of TPMT status in childhood/adolescent ALL patients on maintenance therapy with 6-MP. This was also the case for the IBD patients investigated here, but, unlike Jacobson et al. <xref rid="bib0165" ref-type="bibr">[33]</xref>, we found no correlation between RBC TGN levels and DNA-incorporated dTG in whole blood DNA of IBD patients. Such a lack of correlation is not surprising given the very different cellular compartments and the fact that clinical studies have shown major difference between RBC TGNs and leukocyte cytosolic TGNs in the same blood samples <xref rid="bib0185" ref-type="bibr">[37]</xref>, <xref rid="bib0190" ref-type="bibr">[38]</xref>. Disease biology may also be an important factor and it is critical to understand thiopurine metabolism in relevant target tissues and how this relates to pharmacological markers and clinical responses. With the method described here, sample processing, DNA isolation, digestion and analysis are simple and easily set up in diagnostic laboratories, and this will facilitate a greater understanding of thiopurine pharmacology which is essential if these inexpensive yet effective drugs are to be used to their full potential.</p></sec></body><back><ref-list><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Lennard</surname><given-names>L.</given-names></name><name><surname>Singleton</surname><given-names>H.J.</given-names></name></person-group><article-title>High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample</article-title><source>J. Chromatogr.</source><volume>583</volume><year>1992</year><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">1484095</pub-id></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>C.H.</given-names></name><name><surname>Achkar</surname><given-names>E.</given-names></name></person-group><article-title>Azathioprine therapy for inflammatory bowel disease. A preliminary report</article-title><source>Amer. J. Gastroenterol.</source><volume>54</volume><year>1970</year><fpage>363</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">5478849</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>G.M.</given-names><suffix>II</suffix></name></person-group><article-title>Medical treatment of inflammatory bowel disease</article-title><source>Calif. Med.</source><volume>119</volume><year>1973</year><fpage>21</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">4148269</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Pounder</surname><given-names>R.E.</given-names></name></person-group><article-title>Pancreatic exocrine deficiency, chronic active hepatitis and familial autoallergic haemolytic anaemia</article-title><source>Proc. Roy. Soc. Med.</source><volume>67</volume><year>1974</year><fpage>323</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">4835274</pub-id></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Moens</surname><given-names>C.</given-names></name><name><surname>Brocteur</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of rheumatoid arthritis with immunosuppressive drugs. I. Clinical study</article-title><source>Acta Rheum. Scand.</source><volume>11</volume><year>1965</year><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">4158235</pub-id></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Haglund</surname><given-names>S.</given-names></name><name><surname>Vikingsson</surname><given-names>S.</given-names></name><name><surname>Soderman</surname><given-names>J.</given-names></name><name><surname>Hindorf</surname><given-names>U.</given-names></name><name><surname>Granno</surname><given-names>C.</given-names></name><name><surname>Danelius</surname><given-names>M.</given-names></name><name><surname>Coulthard</surname><given-names>S.</given-names></name><name><surname>Peterson</surname><given-names>C.</given-names></name><name><surname>Almer</surname><given-names>S.</given-names></name></person-group><article-title>The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease</article-title><source>Ther. Drug Monit.</source><volume>33</volume><year>2011</year><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">21311411</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Weinshilboum</surname><given-names>R.M.</given-names></name><name><surname>Sladek</surname><given-names>S.L.</given-names></name></person-group><article-title>Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity</article-title><source>Am. J. Hum. Genet.</source><volume>32</volume><year>1980</year><fpage>651</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">7191632</pub-id></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Coulthard</surname><given-names>S.A.</given-names></name><name><surname>Hogarth</surname><given-names>L.</given-names></name></person-group><article-title>The thiopurines: an update</article-title><source>Invest. New Drugs</source><volume>23</volume><year>2005</year><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">16267626</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Lindqvist</surname><given-names>M.</given-names></name><name><surname>Skoglund</surname><given-names>K.</given-names></name><name><surname>Karlgren</surname><given-names>A.</given-names></name><name><surname>Soderkvist</surname><given-names>P.</given-names></name><name><surname>Peterson</surname><given-names>C.</given-names></name><name><surname>Kidhall</surname><given-names>I.</given-names></name><name><surname>Almer</surname><given-names>S.</given-names></name></person-group><article-title>Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23</article-title><source>Pharmacogenet. Genomics</source><volume>17</volume><year>2007</year><fpage>891</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">17885628</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Lennard</surname><given-names>L.</given-names></name><name><surname>Van Loon</surname><given-names>J.A.</given-names></name><name><surname>Lilleyman</surname><given-names>J.S.</given-names></name><name><surname>Weinshilboum</surname><given-names>R.M.</given-names></name></person-group><article-title>Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations</article-title><source>Clin. Pharm. Ther.</source><volume>41</volume><year>1987</year><fpage>18</fpage><lpage>25</lpage></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Lennard</surname><given-names>L.</given-names></name><name><surname>Van Loon</surname><given-names>J.A.</given-names></name><name><surname>Weinshilboum</surname><given-names>R.M.</given-names></name></person-group><article-title>Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism</article-title><source>Clin. Pharm. Ther.</source><volume>46</volume><year>1989</year><fpage>149</fpage><lpage>154</lpage></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Lennard</surname><given-names>L.</given-names></name><name><surname>Lilleyman</surname><given-names>J.S.</given-names></name><name><surname>Van Loon</surname><given-names>J.</given-names></name><name><surname>Weinshilboum</surname><given-names>R.M.</given-names></name></person-group><article-title>Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia</article-title><source>Lancet</source><volume>336</volume><year>1990</year><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">1973780</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Tiede</surname><given-names>I.</given-names></name><name><surname>Fritz</surname><given-names>G.</given-names></name><name><surname>Strand</surname><given-names>S.</given-names></name><name><surname>Poppe</surname><given-names>D.</given-names></name><name><surname>Dvorsky</surname><given-names>R.</given-names></name><name><surname>Strand</surname><given-names>D.</given-names></name><name><surname>Lehr</surname><given-names>H.A.</given-names></name><name><surname>Wirtz</surname><given-names>S.</given-names></name><name><surname>Becker</surname><given-names>C.</given-names></name><name><surname>Atreya</surname><given-names>R.</given-names></name><name><surname>Mudter</surname><given-names>J.</given-names></name><name><surname>Hildner</surname><given-names>K.</given-names></name><name><surname>Bartsch</surname><given-names>B.</given-names></name><name><surname>Holtmann</surname><given-names>M.</given-names></name><name><surname>Blumberg</surname><given-names>R.</given-names></name><name><surname>Walczak</surname><given-names>H.</given-names></name><name><surname>Iven</surname><given-names>H.</given-names></name><name><surname>Galle</surname><given-names>P.R.</given-names></name><name><surname>Ahmadian</surname><given-names>M.R.</given-names></name><name><surname>Neurath</surname><given-names>M.F.</given-names></name></person-group><article-title>CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes</article-title><source>J. Clin. Invest.</source><volume>111</volume><year>2003</year><fpage>1133</fpage><lpage>1145</lpage><pub-id pub-id-type="pmid">12697733</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Karran</surname><given-names>P.</given-names></name><name><surname>Attard</surname><given-names>N.</given-names></name></person-group><article-title>Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer</article-title><source>Nature Rev. Cancer</source><volume>8</volume><year>2008</year><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">18097462</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Lennard</surname><given-names>L.</given-names></name><name><surname>Lewis</surname><given-names>I.J.</given-names></name><name><surname>Michelagnoli</surname><given-names>M.</given-names></name><name><surname>Lilleyman</surname><given-names>J.S.</given-names></name></person-group><article-title>Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies</article-title><source>Med. Ped. Oncol.</source><volume>29</volume><year>1997</year><fpage>252</fpage><lpage>255</lpage></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>T.R.</given-names></name><name><surname>Swann</surname><given-names>P.F.</given-names></name></person-group><article-title>Cytotoxic mechanism of 6-thioguanine: hMutSalpha the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine</article-title><source>Biochemistry</source><volume>36</volume><year>1997</year><fpage>2501</fpage><lpage>2506</lpage><pub-id pub-id-type="pmid">9054555</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>T.</given-names></name><name><surname>Maddocks</surname><given-names>J.L.</given-names></name></person-group><article-title>Assay of an active metabolite of 6-thioguanine 6-thioguanosine 5'-monophosphate, in human red blood cells</article-title><source>J. Chromatogr.</source><volume>229</volume><year>1982</year><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">7085819</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Lennard</surname><given-names>L.</given-names></name><name><surname>Maddocks</surname><given-names>J.L.</given-names></name></person-group><article-title>Assay of 6-thioguanine nucleotide a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells</article-title><source>J. Pharm. Pharmacol.</source><volume>35</volume><year>1983</year><fpage>15</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">6131958</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>U.</given-names></name><name><surname>Heinkele</surname><given-names>G.</given-names></name><name><surname>Angelberger</surname><given-names>S.</given-names></name><name><surname>Schaeffeler</surname><given-names>E.</given-names></name><name><surname>Lichtenberger</surname><given-names>C.</given-names></name><name><surname>Jaeger</surname><given-names>S.</given-names></name><name><surname>Reinisch</surname><given-names>W.</given-names></name><name><surname>Schwab</surname><given-names>M.</given-names></name></person-group><article-title>Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry</article-title><source>Anal. Chem.</source><volume>84</volume><year>2012</year><fpage>1294</fpage><lpage>1301</lpage><pub-id pub-id-type="pmid">22220820</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Vikingsson</surname><given-names>S.</given-names></name><name><surname>Almer</surname><given-names>S.</given-names></name><name><surname>Peterson</surname><given-names>C.</given-names></name><name><surname>Carlsson</surname><given-names>B.</given-names></name><name><surname>Josefsson</surname><given-names>M.</given-names></name></person-group><article-title>Monitoring of thiopurine metabolites &#x02212; a high-performance liquid chromatography method for clinical use</article-title><source>J. Pharm. Biomed. Anal.</source><volume>75</volume><year>2013</year><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">23261807</pub-id></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Pike</surname><given-names>M.G.</given-names></name><name><surname>Franklin</surname><given-names>C.L.</given-names></name><name><surname>Mays</surname><given-names>D.C.</given-names></name><name><surname>Lipsky</surname><given-names>J.J.</given-names></name><name><surname>Lowry</surname><given-names>P.W.</given-names></name><name><surname>Sandborn</surname><given-names>W.J.</given-names></name></person-group><article-title>Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood</article-title><source>J. Chromatogr. B</source><volume>757</volume><year>2001</year><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>D.J.</given-names></name><name><surname>Slordal</surname><given-names>L.</given-names></name></person-group><article-title>A high-performance liquid chromatographic method for the determination of 6-thioguanine residues in DNA using precolumn derivatization and fluorescence detection</article-title><source>Anal. Biochem.</source><volume>215</volume><year>1993</year><fpage>278</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">8122790</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Cuffari</surname><given-names>C.</given-names></name><name><surname>Seidman</surname><given-names>E.G.</given-names></name><name><surname>Latour</surname><given-names>S.</given-names></name><name><surname>Theoret</surname><given-names>Y.</given-names></name></person-group><article-title>Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy</article-title><source>Can. J. Physiol. Pharmacol.</source><volume>74</volume><year>1996</year><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">8884023</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Osterman</surname><given-names>M.T.</given-names></name><name><surname>Kundu</surname><given-names>R.</given-names></name><name><surname>Lichtenstein</surname><given-names>G.R.</given-names></name><name><surname>Lewis</surname><given-names>J.D.</given-names></name></person-group><article-title>Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis</article-title><source>Gastroenterology</source><volume>130</volume><year>2006</year><fpage>1047</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">16618398</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Konidari</surname><given-names>A.</given-names></name><name><surname>Anagnostopoulos</surname><given-names>A.</given-names></name><name><surname>Bonnett</surname><given-names>L.J.</given-names></name><name><surname>Pirmohamed</surname><given-names>M.</given-names></name><name><surname>El Matary</surname><given-names>W.</given-names></name></person-group><article-title>Thiopurine monitoring in children with inflammatory bowel disease: a systematic review</article-title><source>Brit. J. Clin. Pharmacol.</source><volume>78</volume><year>2014</year><fpage>467</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">24592889</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.N.</given-names></name><name><surname>Kang</surname><given-names>B.</given-names></name><name><surname>Choi</surname><given-names>S.Y.</given-names></name><name><surname>Kim</surname><given-names>M.J.</given-names></name><name><surname>Woo</surname><given-names>S.Y.</given-names></name><name><surname>Kim</surname><given-names>J.W.</given-names></name><name><surname>Choe</surname><given-names>Y.H.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name></person-group><article-title>Relationship between azathioprine dosage 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine</article-title><source>Inflamm. Bowel Dis.</source><volume>21</volume><year>2015</year><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">25851563</pub-id></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Duley</surname><given-names>J.A.</given-names></name><name><surname>Florin</surname><given-names>T.H.</given-names></name></person-group><article-title>Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides</article-title><source>Ther. Drug Monit.</source><volume>27</volume><year>2005</year><fpage>647</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">16175140</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Daly</surname><given-names>A.K.</given-names></name><name><surname>Steen</surname><given-names>V.M.</given-names></name><name><surname>Fairbrother</surname><given-names>K.S.</given-names></name><name><surname>Idle</surname><given-names>J.R.</given-names></name></person-group><article-title>CYP2D6 multiallelism</article-title><source>Meth. Enzymol.</source><volume>272</volume><year>1996</year><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">8791778</pub-id></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Coulthard</surname><given-names>S.A.</given-names></name><name><surname>Hogarth</surname><given-names>L.A.</given-names></name><name><surname>Little</surname><given-names>M.</given-names></name><name><surname>Matheson</surname><given-names>E.C.</given-names></name><name><surname>Redfern</surname><given-names>C.P.F.</given-names></name><name><surname>Minto</surname><given-names>L.</given-names></name><name><surname>Hall</surname><given-names>A.G.</given-names></name></person-group><article-title>The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs</article-title><source>Mol. Pharmacol.</source><volume>62</volume><year>2002</year><fpage>102</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">12065760</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="book" id="sbref0150"><person-group person-group-type="author"><name><surname>FDA</surname></name></person-group><chapter-title>Guidance for Industry: Bioanalytical Method Validation</chapter-title><year>2001</year><publisher-name>FDA</publisher-name></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="book" id="sbref0155"><person-group person-group-type="author"><name><surname>R. Core Team</surname></name></person-group><chapter-title>R: A Language and Environment for Statistical Computing</chapter-title><year>2014</year><publisher-name>R Foundation for Statistical Computing</publisher-name><publisher-loc>Vienna, Austria</publisher-loc></element-citation></ref><ref id="bib0160"><label>32</label><mixed-citation publication-type="other" id="oref0160">A.I. McLeod, Kendall. Kendall rank correlation and Mann-Kendall trend test R package, version 2.2 2011.</mixed-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>J.H.</given-names></name><name><surname>Schmiegelow</surname><given-names>K.</given-names></name><name><surname>Nersting</surname><given-names>J.</given-names></name></person-group><article-title>Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard</article-title><source>J. Chromatogr. B</source><volume>881&#x02013;882</volume><year>2012</year><fpage>115</fpage><lpage>118</lpage></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Ebbesen</surname><given-names>M.S.</given-names></name><name><surname>Nersting</surname><given-names>J.</given-names></name><name><surname>Jacobsen</surname><given-names>J.H.</given-names></name><name><surname>Frandsen</surname><given-names>T.L.</given-names></name><name><surname>Vettenranta</surname><given-names>K.</given-names></name><name><surname>Abramsson</surname><given-names>J.</given-names></name><name><surname>Wesenberg</surname><given-names>F.</given-names></name><name><surname>Schmiegelow</surname><given-names>K.</given-names></name></person-group><article-title>Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes</article-title><source>J. Clin. Pharmacol.</source><volume>53</volume><year>2013</year><fpage>670</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">23585236</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Toft</surname><given-names>N.</given-names></name><name><surname>Birgens</surname><given-names>H.</given-names></name><name><surname>Abrahamsson</surname><given-names>J.</given-names></name><name><surname>Bernell</surname><given-names>P.</given-names></name><name><surname>Griskevicius</surname><given-names>L.</given-names></name><name><surname>Hallbook</surname><given-names>H.</given-names></name><name><surname>Heyman</surname><given-names>M.</given-names></name><name><surname>Holm</surname><given-names>M.S.</given-names></name><name><surname>Hulegardh</surname><given-names>E.</given-names></name><name><surname>Klausen</surname><given-names>T.W.</given-names></name><name><surname>Marquart</surname><given-names>H.V.</given-names></name><name><surname>Jonsson</surname><given-names>O.G.</given-names></name><name><surname>Nielsen</surname><given-names>O.J.</given-names></name><name><surname>Quist-Paulsen</surname><given-names>P.</given-names></name><name><surname>Taskinen</surname><given-names>M.</given-names></name><name><surname>Vaitkeviciene</surname><given-names>G.</given-names></name><name><surname>Vettenranta</surname><given-names>K.</given-names></name><name><surname>Asberg</surname><given-names>A.</given-names></name><name><surname>Schmiegelow</surname><given-names>K.</given-names></name></person-group><article-title>Risk group assignment differs for children and adults 1&#x02013;45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol</article-title><source>Eur. J. Haematol.</source><volume>90</volume><year>2013</year><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">23461707</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>M.J.</given-names></name><name><surname>Lobo</surname><given-names>A.J.</given-names></name><name><surname>Travis</surname><given-names>S.P.</given-names></name></person-group><article-title>Guidelines for the management of inflammatory bowel disease in adults</article-title><source>Gut</source><volume>53</volume><issue>Suppl. 5</issue><year>2004</year><fpage>V1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15306569</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Bergan</surname><given-names>S.</given-names></name><name><surname>Bentdal</surname><given-names>O.</given-names></name><name><surname>Sodal</surname><given-names>G.</given-names></name><name><surname>Brun</surname><given-names>A.</given-names></name><name><surname>Rugstad</surname><given-names>H.E.</given-names></name><name><surname>Stokke</surname><given-names>O.</given-names></name></person-group><article-title>Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts</article-title><source>Ther. Drug Monit.</source><volume>19</volume><year>1997</year><fpage>502</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">9357091</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Lancaster</surname><given-names>D.L.</given-names></name><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>Lennard</surname><given-names>L.</given-names></name><name><surname>Lilleyman</surname><given-names>J.S.</given-names></name></person-group><article-title>Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia</article-title><source>Cancer Chemother. Pharmacol.</source><volume>50</volume><year>2002</year><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">12111109</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p>This study was funded by <funding-source id="gs0005">The BROAD Foundation</funding-source> (IBD-0355R2) and MRC Confidence in Concept funds awarded to Newcastle University. The funding bodies had no role in study design, collection, analysis and interpretation of data, in the writing of the report or in the decision to submit the article for publication. We are grateful to the clinical staff at the East Surrey Hospital, Royal Bournemouth and Christchurch Hospitals, North Tees Hospital, South Tyneside Hospital, City Hospital Sunderland and James Cook Hospital South Tees who contributed patient samples to the study.</p></ack></back><floats-group><fig id="fig0005"><label>Fig. 1</label><caption><p>Schematic summarising the metabolism of 6- MP via the enzymes (Blue text) inosine-monophosphate dehydrogenase (IMPDH), thiopurine methyl-transferase (TPMT), hypoxanthine-guanine phosphoribosyl transferase (HGPRT), inosine tri-phosphatase (ITPase) and guanosine monophosphate synthetase (GMPS). MeMP, methylmercaptopurine; TIMP, thioinosine monophosphate with metabolism to the di- and triphosphates TIDP and TITP, respectively; TXMP, thioxanthine monophosphate; TGMP, thioguanosine monophosphate with metabolism to the di- and tri-phosphates TGDP and TGTP, respectively and incorporation into DNA (for interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).</p></caption><alt-text id="at0215">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><fig id="fig0010"><label>Fig. 2</label><caption><p>LC&#x02013;MS/MS profiles (50&#x000a0;&#x003bc;L injection volume) for (a) dA and dTG standards (125&#x000a0;ng/mL dA and 0.78&#x000a0;ng/mL dTG; peak areas represent 6.25&#x000a0;ng dA and 0.039&#x000a0;ng injected dTG), and (b) a patient on treatment with azathioprine. The additional small peak in (b) between the dA and dTG peaks is thioguanosine. The retention time of the internal standard MeMP-d3 (not shown) was 6.92&#x000a0;min.</p></caption><alt-text id="at0220">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig><table-wrap id="tbl0005" position="float"><label>Table 1</label><caption><p>Mass transitions and optimised MS/MS parameters for analyte quantification, deoxythioguanosine (dTG), deoxyadenosine (dA), Methymercaptopurine-D3 (MeMP-d3).</p></caption><alt-text id="at0225">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Analyte</th><th align="left">Analyte Retention Time (min)</th><th align="left">MRM transition (<italic>m</italic>/<italic>z</italic>)</th><th align="left">Declustering Potential (V)</th><th align="left">Entrance Potential (V)</th><th align="left">Collision Energy (eV)</th><th align="left">Collision exit potential (V)</th></tr></thead><tbody><tr><td align="left">dTG</td><td align="char">6</td><td align="left">284.19 &#x02212;&#x0003e;&#x02009;168.2</td><td align="char">41</td><td align="char">10</td><td align="char">15</td><td align="char">10</td></tr><tr><td align="left">dA</td><td align="char">5.6</td><td align="left">252.30 &#x02212;&#x0003e;&#x02009;136.2</td><td align="char">31</td><td align="char">10</td><td align="char">21</td><td align="char">8</td></tr><tr><td align="left">MeMP-d3</td><td align="char">6.9</td><td align="left">170.1 &#x02212;&#x0003e;&#x02009;152.2</td><td align="char">66</td><td align="char">10</td><td align="char">33</td><td align="char">10</td></tr></tbody></table></table-wrap><table-wrap id="tbl0010" position="float"><label>Table 2</label><caption><p>Standard curve and quality control analyses.</p></caption><alt-text id="at0230">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Analyte</th><th align="left">dA</th><th align="left">dTG</th></tr></thead><tbody><tr><td align="left">LOD (ng injected) <xref rid="tblfn0005" ref-type="table-fn">a</xref></td><td align="left">nd<xref rid="tblfn0030" ref-type="table-fn">f</xref></td><td align="left">0.0003125</td></tr><tr><td align="left">LLOQ (ng) <xref rid="tblfn0010" ref-type="table-fn">b</xref></td><td align="left">nd<xref rid="tblfn0030" ref-type="table-fn">f</xref></td><td align="left">0.000625</td></tr><tr><td align="left"><italic>analytica</italic>l range<break/>(ng injected)</td><td align="left">0.0975&#x000a0;ng to 50&#x000a0;ng</td><td align="left">0.000625&#x000a0;ng&#x02013;10&#x000a0;ng</td></tr><tr><td align="left">average curve<xref rid="tblfn0015" ref-type="table-fn">c</xref></td><td align="left">Y&#x000a0;=&#x000a0;&#x02212;6218126&#x000a0;&#x000d7;<sup>2</sup>&#x000a0;+&#x000a0;26200326x&#x000a0;+&#x000a0;5014429</td><td align="left">y&#x000a0;=&#x000a0;263992&#x000a0;&#x000d7;&#x000a0;+&#x000a0;148.9</td></tr><tr><td align="left">weighting</td><td align="left">1/x<sup>2</sup></td><td align="left">1/x</td></tr><tr><td align="left">fit</td><td align="left">quadratic</td><td align="left">linear</td></tr><tr><td align="left">Intra-day High QC<xref rid="tblfn0020" ref-type="table-fn">d</xref></td><td align="left">3.5%</td><td align="left">4.2%</td></tr><tr><td align="left">Intra-day Mid QC</td><td align="left">7.8%</td><td align="left">7.7%</td></tr><tr><td align="left">Intra-day Low QC</td><td align="left">3.3%</td><td align="left">11.9%</td></tr><tr><td align="left">Inter-day High QC<xref rid="tblfn0025" ref-type="table-fn">e</xref></td><td align="left">7.8%</td><td align="left">8.2%</td></tr><tr><td align="left">Inter-day Med QC</td><td align="left">5.1%</td><td align="left">8.5%</td></tr><tr><td align="left">Inter-day Low QC</td><td align="left">17.0%</td><td align="left">15.9%</td></tr></tbody></table><table-wrap-foot><fn id="tblfn0005"><label>a</label><p id="npar0005">Limit of detection (10&#x000a0;&#x000d7;&#x000a0;baseline).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0010"><label>b</label><p id="npar0010">Lower Limit of Quantification (2&#x000a0;&#x000d7;&#x000a0;LOD).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0015"><label>c</label><p id="npar0015">Calibration curves adjusted R<sup>2</sup>: dA&#x000a0;=&#x000a0;0.991; dTG&#x000a0;=&#x000a0;0.996.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0020"><label>d</label><p id="npar0020">Intra-day, n&#x000a0;=&#x000a0;10.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0025"><label>e</label><p id="npar0025">Inter-day, n&#x000a0;=&#x000a0;5.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0030"><label>f</label><p id="npar0030">nd, not determined: dA standard concentrations were 100-fold higher than for dTG and sensitivity for dA was not relevant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0015" position="float"><label>Table 3</label><caption><p>Consistent results using different starting amounts of DNA for digestion from the same sample. N/D, not detected.</p></caption><alt-text id="at0235">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Amount of DNA digested (&#x003bc;g)</th><th align="left">ng dA<xref rid="tblfn0035" ref-type="table-fn">a</xref> detected</th><th align="left">ng dTG<xref rid="tblfn0040" ref-type="table-fn">b</xref></th><th align="left">Moles dTG/10<sup>6</sup> moles dA</th></tr></thead><tbody><tr><td align="left">5</td><td align="left">10.1</td><td align="left">0.059</td><td align="left">520.7</td></tr><tr><td align="left">2.5</td><td align="left">5.6</td><td align="left">0.031</td><td align="left">493.4</td></tr><tr><td align="left">1.25</td><td align="left">2.5</td><td align="left">0.013</td><td align="left">461.9</td></tr><tr><td align="left">0.625</td><td align="left">1.4</td><td align="left">0.006</td><td align="left">398.2</td></tr><tr><td align="left">Untreated control patient</td><td align="left">8.5</td><td align="left">N/D</td><td align="left">N/D</td></tr><tr><td colspan="4" align="left">&#x02028;&#x02028;</td></tr><tr><td align="left">DNA range</td><td align="left">mean<xref rid="tblfn0045" ref-type="table-fn">c</xref></td><td align="left">Stdev</td><td align="left">CV</td></tr><tr><td align="left">1.25 &#x02212; 5ug</td><td align="left">49.20</td><td align="left">2.94</td><td align="left">6%</td></tr><tr><td align="left">0.625 &#x02212; 5ug</td><td align="left">46.86</td><td align="left">5.27</td><td align="left">11%</td></tr></tbody></table><table-wrap-foot><fn id="tblfn0035"><label>a</label><p id="npar0035">Representing 0.018&#x000a0;&#x003bc;g DNA injected.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0040"><label>b</label><p id="npar0040">Representing 0.18&#x000a0;&#x003bc;g DNA injected.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0045"><label>c</label><p id="npar0045">Moles dTG/10<sup>6</sup>&#x000a0;moles dA.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0020" position="float"><label>Table 4</label><caption><p>Freeze-thaw (FT) stability.</p></caption><alt-text id="at0240">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th colspan="3" align="left">dA<hr/></th><th colspan="3" align="left">dTG<hr/></th></tr><tr><th align="left"/><th align="left">LQC</th><th align="left">MQC</th><th align="left">HQC</th><th align="left">LQC</th><th align="left">MQC</th><th align="left">HQC</th></tr></thead><tbody><tr><td align="left">FT1<sup>a</sup></td><td align="left">0%</td><td align="left">0%</td><td align="left">0%</td><td align="left">0%</td><td align="left">0%</td><td align="left">0%</td></tr><tr><td align="left">FT2<sup>a</sup></td><td align="left">&#x02212;3%</td><td align="left">12%</td><td align="left">4%</td><td align="left">1%</td><td align="left">&#x02212;1%</td><td align="left">8%</td></tr><tr><td align="left">FT3<sup>a</sup></td><td align="left">&#x02212;6%</td><td align="left">4%</td><td align="left">9%</td><td align="left">&#x02212;10%</td><td align="left">&#x02212;13%</td><td align="left">&#x02212;12%</td></tr><tr><td align="left">%CV across all samples</td><td align="left">3%</td><td align="left">6%</td><td align="left">5%</td><td align="left">6%</td><td align="left">8%</td><td align="left">11%</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>Signal change compared to FT cycle 1.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0025" position="float"><label>Table 5</label><caption><p>Low temperate stability.</p></caption><alt-text id="at0245">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th colspan="2" align="left">Moles dTG/10<sup>6</sup> moles dA<hr/></th><th align="left">% difference between days</th></tr><tr><th align="left"/><th align="left">Day 1</th><th align="left">Day 2 (Overnight @4&#x000a0;&#x000b0;C)</th><th align="left"/></tr></thead><tbody><tr><td align="left">LQC</td><td align="left">105.231</td><td align="left">88.495</td><td align="left">&#x02212;16%</td></tr><tr><td align="left">MQC</td><td align="left">66.707</td><td align="left">68.164</td><td align="left">2%</td></tr><tr><td align="left">HQC</td><td align="left">77.813</td><td align="left">86.026</td><td align="left">10%</td></tr></tbody></table></table-wrap><table-wrap id="tbl0030" position="float"><label>Table 6</label><caption><p>Quantification of incorporated dTG (amount detected in 50&#x000a0;&#x003bc;L sample, representing 0.18&#x000a0;&#x003bc;g DNA, injected onto column) in NBC in relation to clinical parameters from patients (ID 1&#x02013;20) treated with azathioprine (dose) and three untreated patients (A&#x02013;C). ID, patient identifier; N/A, data not available; N/D, analyte not detected.</p></caption><alt-text id="at0250">Table 6</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">ID</th><th align="left">Disease<xref rid="tblfn0050" ref-type="table-fn">a</xref></th><th align="left">dose</th><th align="left">ng dA<xref rid="tblfn0055" ref-type="table-fn">b</xref></th><th align="left">ng dTG</th><th align="left">moles dTG/10<sup>6</sup> moles dA</th><th align="left">fmoles dTG/&#x003bc;g DNA</th><th align="left">WCC<xref rid="tblfn0060" ref-type="table-fn">c</xref></th><th align="left">Neut<xref rid="tblfn0060" ref-type="table-fn">c</xref></th><th align="left">ALT<xref rid="tblfn0060" ref-type="table-fn">c</xref></th><th align="left">AP<xref rid="tblfn0060" ref-type="table-fn">c</xref></th><th align="left">TPMT</th><th align="left">RBC TGN<xref rid="tblfn0060" ref-type="table-fn">c</xref></th><th align="left">RBC MMP<xref rid="tblfn0060" ref-type="table-fn">c</xref></th></tr></thead><tbody><tr><td align="left">1</td><td align="left">CD</td><td align="char">100</td><td align="char">3.97</td><td align="left">0.003</td><td align="left">59.2</td><td align="left">52.0</td><td align="char">10.9</td><td align="char">9.4</td><td align="char">10</td><td align="char">60</td><td align="left">70</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">2</td><td align="left">UC</td><td align="char">150</td><td align="char">9.25</td><td align="left">0.035</td><td align="left">333.2</td><td align="left">682.2</td><td align="char">5.4</td><td align="char">3.3</td><td align="char">20</td><td align="char">50</td><td align="left">70</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">3</td><td align="left">UC</td><td align="char">150</td><td align="char">3.115</td><td align="left">0.001</td><td align="left">20.2</td><td align="left">13.9</td><td align="char">4.3</td><td align="char">3</td><td align="char">29</td><td align="char">89</td><td align="left">87</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">4</td><td align="left">UC</td><td align="char">125</td><td align="char">7.4</td><td align="left">0.011</td><td align="left">135.4</td><td align="left">221.8</td><td align="char">3.8</td><td align="char">2.4</td><td align="char">5</td><td align="char">42</td><td align="left">14</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">5</td><td align="left">CD</td><td align="char">200</td><td align="char">4.62</td><td align="left">0.027</td><td align="left">524.1</td><td align="left">535.9</td><td align="char">3.4</td><td align="char">2.2</td><td align="char">21</td><td align="char">37</td><td align="left">70</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">6</td><td align="left">UC</td><td align="char">150</td><td align="char">4.555</td><td align="left">0.005</td><td align="left">97.4</td><td align="left">98.2</td><td align="char">9.3</td><td align="char">5.1</td><td align="char">16</td><td align="char">94</td><td align="left">123</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">7</td><td align="left">CD</td><td align="char">150</td><td align="char">14.7</td><td align="left">0.022</td><td align="left">133.3</td><td align="left">433.8</td><td align="char">5.5</td><td align="char">3.6</td><td align="char">13</td><td align="char">52</td><td align="left">102</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">8</td><td align="left">UC</td><td align="char">100</td><td align="char">6.1</td><td align="left">0.003</td><td align="left">36.3</td><td align="left">49.1</td><td align="char">5</td><td align="char">3</td><td align="char">13</td><td align="char">70</td><td align="left">78</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">9</td><td align="left">CD</td><td align="char">100</td><td align="char">4.185</td><td align="left">0.004</td><td align="left">74.2</td><td align="left">68.7</td><td align="char">9</td><td align="char">8</td><td align="char">11</td><td align="char">63</td><td align="left">80</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">10</td><td align="left">CD</td><td align="char">50</td><td align="char">7.35</td><td align="left">0.002</td><td align="left">26.5</td><td align="left">43.2</td><td align="char">10.5</td><td align="char">8.3</td><td align="char">18</td><td align="char">91</td><td align="left">102</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">11</td><td align="left">UC</td><td align="char">150</td><td align="char">11.4</td><td align="left">0.006</td><td align="left">46.7</td><td align="left">117.8</td><td align="char">8</td><td align="char">4</td><td align="char">15</td><td align="char">86</td><td align="left">81</td><td align="left">148</td><td align="left">412</td></tr><tr><td align="left">12</td><td align="left">UC</td><td align="char">200</td><td align="char">6.2</td><td align="left">0.013</td><td align="left">178.8</td><td align="left">245.4</td><td align="char">5.8</td><td align="char">4.1</td><td align="char">22</td><td align="char">71</td><td align="left">N/A</td><td align="left">296</td><td align="left">6698</td></tr><tr><td align="left">13</td><td align="left">CD</td><td align="char">42</td><td align="char">11.95</td><td align="left">0.024</td><td align="left">181.1</td><td align="left">479.0</td><td align="char">5</td><td align="char">2.9</td><td align="char">14</td><td align="char">16</td><td align="left">N/A</td><td align="left">522</td><td align="left">0</td></tr><tr><td align="left">14</td><td align="left">UC</td><td align="char">25</td><td align="char">5.15</td><td align="left">0.008</td><td align="left">129.2</td><td align="left">147.2</td><td align="char">3.8</td><td align="char">2.7</td><td align="char">16</td><td align="char">78</td><td align="left">N/A</td><td align="left">318</td><td align="left">0</td></tr><tr><td align="left">15</td><td align="left">CD</td><td align="char">200</td><td align="char">6.45</td><td align="left">0.002</td><td align="left">27.5</td><td align="left">39.3</td><td align="char">9.2</td><td align="char">9</td><td align="char">8</td><td align="char">80</td><td align="left">94</td><td align="left">559</td><td align="left">0</td></tr><tr><td align="left">16</td><td align="left">CD</td><td align="char">150</td><td align="char">4.77</td><td align="left">0.005</td><td align="left">89.3</td><td align="left">94.2</td><td align="char">8</td><td align="char">5.7</td><td align="char">16</td><td align="char">64</td><td align="left">92</td><td align="left">120</td><td align="left">221</td></tr><tr><td align="left">17</td><td align="left">UC</td><td align="char">175</td><td align="char">1.785</td><td align="left">0.019</td><td align="left">921.7</td><td align="left">364.2</td><td align="char">7.8</td><td align="char">5.7</td><td align="char">13</td><td align="char">58</td><td align="left">N/A</td><td align="left">293</td><td align="left">363</td></tr><tr><td align="left">18</td><td align="left">UC</td><td align="char">100</td><td align="char">7.2</td><td align="left">0.032</td><td align="left">393.6</td><td align="left">627.2</td><td align="char">3.3</td><td align="char">2.4</td><td align="char">15</td><td align="char">80</td><td align="left">116</td><td align="left">477</td><td align="left">219</td></tr><tr><td align="left">19</td><td align="left">CD</td><td align="char">75</td><td align="char">14.45</td><td align="left">0.007</td><td align="left">44.5</td><td align="left">142.3</td><td align="char">6.3</td><td align="char">4</td><td align="char">15</td><td align="char">100</td><td align="left">100</td><td align="left">80</td><td align="left">320</td></tr><tr><td align="left">20</td><td align="left">CD</td><td align="char">200</td><td align="char">3.125</td><td align="left">0.048</td><td align="left">1359.5</td><td align="left">940.3</td><td align="char">5.1</td><td align="char">3</td><td align="char">28</td><td align="char">45</td><td align="left">94</td><td align="left">169</td><td align="left">6398</td></tr><tr><td align="left">A</td><td align="left">UC</td><td align="char">0</td><td align="char">10</td><td align="left">N/D</td><td align="left">N/D</td><td align="left">N/D</td><td align="char">4.6</td><td align="char">3.2</td><td align="char">26</td><td align="char">202</td><td align="left">126</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">B</td><td align="left">UC</td><td align="char">0</td><td align="char">9.6</td><td align="left">N/D</td><td align="left">N/D</td><td align="left">N/D</td><td align="char">3.6</td><td align="char">2.3</td><td align="char">19</td><td align="char">52</td><td align="left">134</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">C</td><td align="left">CD</td><td align="char">0</td><td align="char">8.45</td><td align="left">N/D</td><td align="left">N/D</td><td align="left">N/D</td><td align="char">12.3</td><td align="char">10.2</td><td align="char">20</td><td align="char">85</td><td align="left">81</td><td align="left">N/A</td><td align="left">N/A</td></tr></tbody></table><table-wrap-foot><fn id="tblfn0050"><label>a</label><p id="npar0050">Crohn&#x02019;s Disease, CD; Ulcerative colitis UC.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0055"><label>b</label><p id="npar0055">Representing 0.018&#x000a0;&#x003bc;g DNA injected.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0060"><label>c</label><p id="npar0060">Normal ranges: White cell count (WCC), 4&#x02013;11&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>/L; Neutrophils (Neut), 2.5&#x02013;7.5&#x000a0;&#x000d7;&#x000a0;10<sup>9</sup>/L; Alanine aminotransferase (ALT), 7&#x02013;56&#x000a0;U/L; Alkaline Phosphatase (AP), 44&#x02013;147 IU/L; TPMT, 70&#x02013;110 mU/L; RBC TGNs, reference range 235&#x02013;450&#x000a0;pmol/8&#x000a0;&#x000d7;&#x000a0;10<sup>8</sup> RBC.</p></fn></table-wrap-foot></table-wrap></floats-group></article>